Geneva, Switzerland and Boston, MA -- January 4, 2021 -- ObsEva SA 
(NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company 
developing and commercializing novel therapies to improve women's 
reproductive health, today announced the appointment of David Renas as 
Chief Financial Officer (CFO) and member of the company's Executive 
Committee, effective today. He will be based in the U.S. 
 
   "David has demonstrated a track record of leadership and we are 
delighted to welcome him onto the executive team," said Brian 
O'Callaghan, Chief Executive Officer of ObsEva. "I'm confident he will 
play a key role in further strengthening our relationships with 
investors and potential partners as we prepare to file a new drug 
application (NDA) in the U.S. in the first half of 2021 for Yselty, for 
the treatment of heavy menstrual bleeding and pain associated with 
uterine fibroids in pre-menopausal women, and further develop Ebopiprant 
for the treatment of pre-term labor following the recent release of our 
positive Ph II data." "I would also like to thank our Chief 
Administrative Officer (CAO), Fabien de Ladonchamps, for the wonderful 
job he has done as interim CFO". 
 
   David Renas joins ObsEva with more than 30 years of financial and legal 
experience, including 15 years within the pharmaceutical and life 
sciences industry. Most recently, he served as CFO at Petra Pharma and 
CFO and General Counsel at Sangart, where amongst other accomplishments 
he helped guide the company through 11 clinical trials conducted across 
20 countries. David Renas also served as a Partner at Adkins Black LLP. 
Prior to focusing on the life sciences industry, he was an attorney in 
private practice with Gray Cary Ware & Freidenrich (now DLA Piper) and 
Foley & Lardner, and a CPA at Deloitte. David Renas holds a Bachelor of 
Arts in Economics from Stanford University and a Juris Doctorate from 
the University of California at Davis. 
 
   "I am thrilled to be joining as CFO at such an important time in the 
development of ObsEva which has recently submitted a Marketing 
Authorization Application (MAA) for its lead product Yselty for uterine 
fibroids to the European Medicines Agency (EMA) and has an anticipated 
NDA submission in 1H 2021. I look forward to working with the 
exceptional team on this exciting journey," said David Renas. 
 
 
 
   About ObsEva 
 
   ObsEva is a biopharmaceutical company developing and commercializing 
novel therapies to improve women's reproductive health and pregnancy. 
Through strategic in-licensing and disciplined drug development, ObsEva 
has established a late-stage clinical pipeline with development programs 
focused on treating endometriosis, uterine fibroids, preterm labor, and 
improving embryo transfer outcomes following in vitro fertilization. 
ObsEva is listed on the Nasdaq Global Select Market and is trading under 
the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is 
trading under the ticker symbol "OBSN". For more information, please 
visit www.ObsEva.com. 
 
 
 
   Cautionary Note Regarding Forward Looking Statements 
 
   Any statements contained in this press release that do not describe 
historical facts may constitute forward-looking statements as that term 
is defined in the Private Securities Litigation Reform Act of 1995. 
These statements may be identified by words such as "believe," "expect," 
"may," "plan," "potential," "will," and similar expressions, and are 
based on ObsEva's current beliefs and expectations. These 
forward-looking statements include expectations regarding the clinical 
development of ObsEva's product candidates, and ObsEva's plan to submit 
its MAA in Europe and NDA in the United States. These statements involve 
risks and uncertainties that could cause actual results to differ 
materially from those reflected in such statements. Risks and 
uncertainties that may cause actual results to differ materially include 
uncertainties inherent in the conduct of clinical trials, clinical 
development and related interactions with regulators, , ObsEva's 
reliance on third parties over which it may not always have full control, 
the impact of the novel coronavirus outbreak, and other risks and 
uncertainties that are described in the Risk Factors section of ObsEva's 
Annual Report on Form 20-F for the year ended December 31, 2019, the 
Risk Factors disclosed in ObsEva's Report on Form 6-K filed with the 
Securities and Exchange Commission (SEC) on November 5, 2020 and other 
filings ObsEva makes with the SEC. These documents are available on the 
Investors page of ObsEva's website at www.ObsEva.com. Any 
forward-looking statements speak only as of the date of this press 
release and are based on information available to ObsEva as of the date 
of this release, and ObsEva assumes no obligation to, and does not 
intend to, update any forward-looking statements, whether as a result of 
new information, future events or otherwise. 
 
 
 
   For further information, please contact: 
 
   CEO Office contact 
 
   Shauna Dillon 
 
   Shauna.dillon@ 
https://www.globenewswire.com/Tracker?data=zWKiMCFQL6fj-wImFjd1n6FwscRkHVYGx0yXWfKIHrFvIm0P8IOM2X_7wuS9tRsrFSEbspGRPFARM_tL4DcSMg== 
obseva.ch 
 
   +41 22 552 1550 
 
 
 
 
 
 
 
   Attachment 
 
 
   -- Press release in pdf 
      https://ml-eu.globenewswire.com/Resource/Download/672178c6-5d0d-4e00-b176-867aec122b8d

(END) Dow Jones Newswires

January 04, 2021 01:00 ET (06:00 GMT)